Peripheral Arterial Disease Concept

subject area of

• A MultiCenter Pilot Randomized Controlled Trial of Remote Ischemic Preconditioning in Major Vascular Surgery  Academic Article
• A National Canadian Survey of Antithrombotic Therapy After Urgent and Emergent Limb Revascularization  Academic Article
• Anticoagulation therapy in 2015: where we are and where we are going  Academic Article
• Antithrombotic Agents  Academic Article
• Antithrombotic Therapy for Peripheral Artery Disease  Academic Article
• Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making  Academic Article
• Antithrombotics in stable peripheral artery disease  Academic Article
• Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus  Academic Article
• Assessing Limb Outcomes in Drug Trials in Peripheral Artery Disease: The Need for a Universal and Pragmatic Definition  Academic Article
• Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review  Academic Article
• Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis  Academic Article
• Building Your Peripheral Artery Disease Toolkit: Medical Management of Peripheral Artery Disease in 2022  Academic Article
• COMPASS for Vascular Surgeons  Academic Article
• Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease  Academic Article
• Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up  Academic Article
• Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease  Academic Article
• Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk  Academic Article
• Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1  Academic Article
• Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial  Academic Article
• Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease  Academic Article
• Consensus Document on Intermittent Claudication from the Central European Vascular Forum (C.E.V.F.)-3rd revision (2013) with the sharing of the Mediterranean League of Angiology and Vascular Surgery, and the North Africa and Middle East Chapter of International Union of Angiology.  Academic Article
• Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial  Academic Article
• Diet and Nutrition in Peripheral Artery Disease: A Systematic Review  Academic Article
• Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort  Academic Article
• Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence  Academic Article
• Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances  Academic Article
• Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial  Academic Article
• Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial  Academic Article
• Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes  Academic Article
• Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD  Academic Article
• Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease  Academic Article
• Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD  Academic Article
• Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease  Academic Article
• External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry  Academic Article
• External applicability of the COMPASS trial: the Western Denmark Heart Registry  Academic Article
• Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease  Academic Article
• Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease  Academic Article
• How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?  Academic Article
• Identifying and Treating Young Patients at Risk for Cardiovascular Events  Academic Article
• Impact of Arterial Procedures on Coagulation and Fibrinolysis – A Pilot Study  Academic Article
• Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD  Academic Article
• Inclusion of People With Peripheral Artery Disease in Cardiac Rehabilitation Programs: A Pan-Canadian Survey  Academic Article
• Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease  Academic Article
• Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy  Academic Article
• Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48  Academic Article
• Leukotrienes biosynthesis in vascular surgery patients during perioperative period.  Academic Article
• Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial  Academic Article
• Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials  Academic Article
• Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial  Academic Article
• Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease  Academic Article
• Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin  Academic Article
• Microvascular disease increases the risk of lower limb amputation – A Western Danish cohort study  Academic Article
• Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease  Academic Article
• Myocardial injury after endovascular revascularization in critical limb ischemia predicts 1-year mortality: a prospective observational cohort study  Academic Article
• New developments in anticoagulants: Past, present and future  Academic Article
• Outcome of aortoiliac, femoropopliteal and infrapopliteal endovascular interventions in lesions categorised by TASC classification  Academic Article
• Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia  Academic Article
• Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry  Academic Article
• Patients with Peripheral Artery Disease in the COMPASS Trial  Academic Article
• Perioperative cardiovascular complications rate and activity of coagulation and fibrinolysis among patients undergoing vascular surgery for peripheral artery disease and abdominal aortic aneurysm  Academic Article
• Peripheral Artery Disease: A High-Risk Yet Understudied, Underdiagnosed, and Undertreated Condition—A Call to Action  Academic Article
• Position Statement on Noninvasive Imaging of Peripheral Arterial Disease by the Society of Interventional Radiology and the Canadian Interventional Radiology Association  Academic Article
• Prevention and Management of Urgent/Emergent Limb Ischemia  Academic Article
• Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone  Academic Article
• Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)  Academic Article
• Real-Time Quantitative Measurements of Foot Perfusion in Patients With Critical Limb Ischemia  Academic Article
• Review of aspirin and clopidogrel resistance in peripheral arterial disease  Academic Article
• Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial  Academic Article
• Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis  Academic Article
• Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction  Academic Article
• Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease  Academic Article
• Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease  Academic Article
• Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization  Academic Article
• Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios  Academic Article
• Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization  Academic Article
• Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial  Academic Article
• Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease  Academic Article
• Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment  Academic Article
• Rivaroxaban in Peripheral Artery Disease after Revascularization  Academic Article
• Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits  Academic Article
• Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial  Academic Article
• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial  Academic Article
• Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization  Academic Article
• Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin  Academic Article
• Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD  Academic Article
• Social Deprivation and Peripheral Artery Disease  Academic Article
• Stroke Outcomes in the COMPASS Trial  Academic Article
• Subintimal recanalization of peripheral chronic occlusive arterial disease with modified transseptal needle  Academic Article
• Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease  Academic Article
• The Association of Cannabis Use Disorder with Acute Limb Ischemia and Critical Limb Ischemia  Academic Article
• The Time Has Come for Vascular Medicine in Canada  Academic Article
• The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial  Academic Article
• The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era  Academic Article
• The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial  Academic Article
• The use of local anesthesia to perform lower limb revascularization in the fragile patient with critical limb ischemia.  Academic Article
• Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study  Academic Article
• Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial  Academic Article
• Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial  Academic Article
• Urinary cysteinyl leukotrienes in one-year follow-up of percutaneous transluminal angioplasty for peripheral arterial occlusive disease  Academic Article
• Urinary fatty acid binding protein 3 (uFABP3) is a potential biomarker for peripheral arterial disease  Academic Article
• Women and Peripheral Arterial Disease: A Review of Sex Differences in Epidemiology, Clinical Manifestations, and Outcomes  Academic Article
• Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both  Academic Article
• miR-29c-3p is an Effective Biomarker of Abdominal Aortic Aneurysm in Patients Undergoing Elective Surgery  Academic Article